Experienced in Teratocarcinosarcoma

Dr. Jameel M. Muzaffar

Hematology Oncology | Hematology | Oncology
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Teratocarcinosarcoma
Duke Health Integrated Practice Inc
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jameel Muzaffar is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Muzaffar is rated as an Experienced provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Adenoid Cystic Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Epithelial-Myoepithelial Carcinoma, Mastoidectomy, and Septoplasty. Dr. Muzaffar is currently accepting new patients.

His clinical research consists of co-authoring 125 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Duke Regional Hospital
Uh Cleveland Medical Center
Duke University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

DUKE HEALTH INTEGRATED PRACTICE INC
40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drugs: BCA101, Pembrolizumab
Study Phase: Phase 1
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Effect of Prolonged Nightly Fasting (PNF) on Immunotherapy Treatment Outcomes in Patients With Advanced Head and Neck Cancer (HNSCC)-Role of Gut Microbiome
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Behavioral
Study Phase: Not Applicable
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drugs: APG-115, Carboplatin
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Cetuximab
Study Phase: Phase 1/Phase 2
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, IRX-2
Study Phase: Phase 1
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Enrollment Status: Terminated
Publish Date: June 24, 2024
Intervention Type: Drug
Study Drug: Rivoceranib
Study Phase: Phase 2
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
A Single Arm Phase II Study of Cemiplimab-rwlc in Immunocompromised Patients With Unresectable Locally Recurrent and/or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Enrollment Status: Terminated
Publish Date: November 04, 2022
Intervention Type: Drug
Study Drug: Cemiplimab-RWLC
Study Phase: Phase 2
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

124 Total Publications

Long-term survival outcomes of temporal bone resection and reconstruction at a UK tertiary skull base centre.
Long-term survival outcomes of temporal bone resection and reconstruction at a UK tertiary skull base centre.
Journal: The Journal of laryngology and otology
Published: December 05, 2025
Similar Doctors
Advanced in Teratocarcinosarcoma
Dr. April Salama
Hematology | Oncology
Advanced in Teratocarcinosarcoma
Dr. April Salama
Hematology | Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (0.3 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

April Salama is a Hematologist and an Oncologist in Durham, North Carolina. Dr. Salama is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Posterior Fossa Tumor.

Experienced in Teratocarcinosarcoma
Dr. Vidhya Karivedu
Hematology Oncology | Oncology
Experienced in Teratocarcinosarcoma
Dr. Vidhya Karivedu
Hematology Oncology | Oncology

Duke Health Integrated Practice Inc

3404 Wake Forest Rd, Suite 200, 
Raleigh, NC 
 (21.6 miles away)
919-684-8111
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Vidhya Karivedu is a Hematologist Oncology specialist and an Oncologist in Raleigh, North Carolina. Dr. Karivedu is rated as an Advanced provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Metastatic Uveal Melanoma, Sinus Cancer, Thyroidectomy, and Gastrostomy. Dr. Karivedu is currently accepting new patients.

Experienced in Teratocarcinosarcoma
Dr. Jared M. Weiss
Hematology Oncology | Hematology | Oncology
Experienced in Teratocarcinosarcoma
Dr. Jared M. Weiss
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

2801 Blue Ridge Rd, 
Raleigh, NC 
 (18.1 miles away)
984-974-0500
Languages Spoken:
English, French, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jared Weiss is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Weiss is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Weiss is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Muzaffar's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile